#AACR26 In CheckMate 77T, ctDNA clearance much more likely with perioperative nivolumab (75% vs 46%) and clearance with nivo more strongl...

Back to meeting Original

Back to meeting

Stephen V Liu, MD· @StephenVLiu · X·2026-04-19 06:46· 2026-04-19Score60

nivolumab

Reading

Immunotherapy: CAR-T in solid tumors, mRNA vaccines, TCR-T

局部 nivolumab · Oral pre-cancer clinical response 85%, 1-year clearance 82%

Body

#AACR26 In CheckMate 77T, ctDNA clearance much more likely with perioperative nivolumab (75% vs 46%) and clearance with nivo more strongly associated with pCR (70%) than placebo (18%). Those who do not clear ctDNA have virtually no chance for pCR. Escalation strategy here?

Heat 4 · 3 likes · 1 reply · 0 reposts

Conference abstracts

CT149NCT05502315matched by 药名 cabozantinib

A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis

Justine Panian, Lin Liu, Minya Pu, Emily Pittman, Samuel Pena, Archana Ajmera, Yu-Wei Chen, Christos Kyriakopoulos, Qian Qin, James Michael Randall, Tian Zhang, Joshua Michael Lang, Akash Patnaik, Rana R. McKay

Read the abstract →

Source: Stephen V Liu, MD · x.com